Interestingly, the expression of the IGF1 receptor in the liver of patients with NAFLD is also increased, which probably acts as a compensatory mechanism to maintain the beneficial effects of IGF1 (38). Here, IGF1 is linked to metabolic dysfunction-associated steatotic liver disease.